Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 ; volume:12 ; number:1 ; day:1 ; month:10 ; year:2022 ; pages:1-11 ; date:12.2022
EJNMMI Research ; 12, Heft 1 (1.10.2022), 1-11, 12.2022
- Creator
-
Meyer, Catherine
Prasad, Vikas
Stuparu, Andreea
Kletting, Peter
Glatting, Gerhard
Miksch, Jonathan
Solbach, Christoph
Lueckerath, Katharina
Nyiranshuti, Lea
Zhu, Shaojun
Czernin, Johannes
Beer, Ambros J.
Slavik, Roger
Calais, Jeremie
Dahlbom, Magnus
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-022-00935-6
- URN
-
urn:nbn:de:101:1-2022122021113540474530
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Meyer, Catherine
- Prasad, Vikas
- Stuparu, Andreea
- Kletting, Peter
- Glatting, Gerhard
- Miksch, Jonathan
- Solbach, Christoph
- Lueckerath, Katharina
- Nyiranshuti, Lea
- Zhu, Shaojun
- Czernin, Johannes
- Beer, Ambros J.
- Slavik, Roger
- Calais, Jeremie
- Dahlbom, Magnus
- SpringerLink (Online service)
Other Objects (12)
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma